ArticleJournal of clinical tuberculosis and other mycobacterial diseases2026
Drivers of drug-resistant tuberculosis treatment initiation delay at three tertiary health facilities in Uganda: A mixed-methods study.
Article in Journal of clinical tuberculosis and other mycobacterial diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Background: Timely treatment initiation is central to drug-resistant tuberculosis (DR-TB) control. Uganda's National TB and Leprosy Programme recommends DR-TB treatment initiation within seven (Okethwangu et al., 2019 (7)) days of rifampicin-resistant TB (RR-TB) diagnosis, but the extent of delay and its drivers are poorly documented at tertiary hospitals in Uganda. This study aimed to determine the prevalence and drivers of DR-TB treatment initiation delay at three tertiary hospitals in Uganda. Methods: A mixed-methods cross-sectional study conducted at Mulago National Referral Hospital (NRH), Hoima Regional Referral Hospital (RRH), and Arua RRH (December 2018-March 2019), enrolling 203 patients with Xpert MTB/RIF-confirmed RR-TB who had started DR-TB treatment. Data was from MDR-TB registers, patient charts, structured questionnaires, and 15 key informant interviews with healthcare workers. Delay was defined as treatment initiation more than seven (Okethwangu et al., 2019 (7)) days after diagnosis. Poisson regression with robust standard errors identified associated factors for delay. Results: DR-TB treatment delay occurred in 65.5% (133/203) of patients overall (73.6% Mulago, 53.9% Hoima, 48.6% Arua), with median diagnosis-to-treatment time of ten (Tefera et al., 2019 (10)) days (IQR 6-20). HIV-positive status (aRR 1.48), female sex (aRR 1.31), and age ≥ 35 years (aRR 1.32) were independently associated with delay at the diagnostic level, while MDR-TB awareness was protective (aRR 0.71) and care at Mulago NRH increased delay risk (aRR 1.65). Qualitative findings pointed to delayed result notification, incomplete laboratory forms, missing baseline investigation equipment, and lack of transport funds as delay drivers. Conclusions: Nearly two-thirds of DR-TB patients exceed the national seven (7)-day treatment initiation target, mainly affecting HIV-positives, women, older adults, and those at the NRH. Improved result notification, patient tracing, decentralised diagnostics, and community awareness campaigns are needed to reduce delays.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.